Gyre Therapeutics (GYRE) Intangibles (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Intangibles of $5.8 million for Q1 2026, up 4.75% year-over-year from $5.6 million in Q1 2025, and up 1.62% quarter-over-quarter from $5.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Intangibles (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Intangibles for 10 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 4.75% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 4.75% YoY), while the FY2025 annual figure was $5.8 million, up 2006.23% from the prior year.
- Intangibles rose to $5.8 million in Q1 2026 per GYRE's latest filing, from $5.8 million in the prior quarter.
- Across five years, Intangibles topped out at $5.8 million in Q1 2026 and bottomed at $184000.0 in Q3 2024.
- Historically, Intangibles has averaged $2.9 million across 5 years, with a median of $2.0 million in 2022.
- Annual changes were most pronounced in 2023 — Intangibles plunged 65.6% — and 2025, when it jumped 2745.92%.
- Gyre Therapeutics' Intangibles stood at $2.0 million in 2022, then slumped by 65.6% to $701000.0 in 2023, then slumped by 61.06% to $273000.0 in 2024, then surged by 2006.23% to $5.8 million in 2025, then advanced by 1.62% to $5.8 million in 2026.
- Business Quant data shows GYRE's Intangibles at $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 5.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.94 Mn |
| Mar 31, 2026 | 5.84 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 5.63 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 196,000.00 |
| Dec 31, 2023 | 701,000.00 |
| Dec 31, 2022 | 2.04 Mn |
| Dec 31, 2014 | 296,000.00 |
| Jun 30, 2014 | 89,000.00 |
| Mar 31, 2014 | 93,000.00 |
| Dec 31, 2013 | 296,000.00 |
| Sep 30, 2013 | 102,000.00 |
| Jun 30, 2013 | 106,000.00 |
| Mar 31, 2013 | 110,000.00 |
| Dec 31, 2012 | 115,000.00 |